The Swiss drug giant Roche has agreed to pay $390 million upfront for a Lexington, Mass., biotech that has developed experimental drugs for fibrotic diseases, including a compound to treat a rare and fatal progressive lung disease.
Roche is buying Promedior to obtain its entire medicine portfolio — including its lead drug candidate, which showed encouraging results in a midstage clinical trial to treat idiopathic pulmonary fibrosis, a lung disorder.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Individual plans
Group plans
To read the rest of this story subscribe to STAT+.